| Mgmt Confidence | High confidence in 12% long-term EPS growth target and flywheel execution. |
|---|---|
| Demand Visibility | Serving 47 million members; focus on Medicaid redetermination continuity. |
| Margin Trends | Focus on bending cost curve via Carelon and transforming operating costs. |
| Op. Leverage | Generative AI deployment to enhance efficiency and automate tasks across workflows. |
| Pricing Power | Aligning commercial pricing to post-pandemic cost structures in 2024. |
| Vol vs Price | Growth driven by Carelon penetration and health benefit membership flywheel. |
| Segment Growth | Carelon to drive greater proportion of earnings; Medicare Advantage needs optimization. |
| New Clients | Expanding Carelon services to external employer and health plan members. |
| Capex & Debt | 50% free cash flow to M&A/reinvestment; 50% to shareholders. |
| Regulatory | Navigating Medicaid redeterminations and Medicare Advantage risk model changes. |
| Commentary | Strategic focus on a 'virtuous flywheel' where health benefits drive Carelon. |
| New Launches | BioPlus scaling, advanced home delivery pharmacy, and new Carelon risk offerings. |
Growth
Historical 15% EPS CAGR over six years; targeting 12% long-term EPS growth.
Outlook
Targeting at least 12% long-term compound annual growth in adjusted diluted EPS.
Risks
Medicaid redeterminations and Medicare Advantage risk model changes present headwinds to membership and margins.
The company's earnings call, NYSE: ELV, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Elevance Health, Inc.: key numbers
- Share price
- $446.28Close, Nov 16
- Market cap
- $96.4B
- Shares outstanding
- 216.06MLatest SEC cover page
- Sector
- Finance
- Industry
- Hospital & Medical Service PlansSIC 6324
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Elevance Health, Inc.
All →Elevance Health Investor Meeting
Elevance Health officers are meeting with investors and analysts to reaffirm the company's full-year 2026 financial guidance. The company continues to expect adjusted shareholders’ earnings of at least $29.00 per diluted share and a benefit expense ratio of 90.2% plus or minus 50 basis points.
Elevance Health EVP & Chief Digital Info Ofr Ratnakar Lavu Sells $572K of Stock
Ratnakar Lavu, EVP & Chief Digital Info Ofr, sold 1,300 shares of Elevance Health, Inc. at $440.00 a share, worth $572K in total on Nov 5, 2026. Shares held after the trade: 14,849 (-8.1%).
- Value
- $572K
- Shares
- 1,300
- Price
- $440.00
- Role
- EVP & Chief Digital Info Ofr
- Holding change
- -8.1%
- Trade date
- Nov 5, 2026
Elevance Health EVP & CFO Mark Kaye Sells $4.66M of Stock
Mark Kaye, EVP & CFO, sold 10,584 shares of Elevance Health, Inc. at $434.00 to $447.19 a share (average $440.13) in 13 transactions, worth $4.66M in total on Oct 22, 2026. Shares held after the trade: 19,919 (-1.4%).
- Value
- $4.66M
- Shares
- 10,584
- Average price
- $440.13
- Role
- EVP & CFO
- Holding change
- -1.4%
- Trade date
- Oct 22, 2026
Elevance Health Q3 2026 Results: Net Income $1.36B, Up 14.8% YoY
For the nine months ended September 30, 2026, Elevance Health reported total operating revenue of $149.8 billion, a slight increase from $148.3 billion in the prior year period. However, shareholders' net income decreased to $4.59 billion compared to $5.12 billion in 2025, primarily driven by higher operating expenses and a decrease in net income for the nine-month period.
- Key figure
- Net income $1.36B · +14.8% YoY
Elevance Health Financial Results
Elevance Health reported Q3 2026 operating revenue of $50.4 billion and raised its full-year 2026 adjusted diluted EPS guidance to at least $29.00. The results were driven by improved operating performance in Medicare Advantage and Individual ACA, alongside growth in CarelonRx product revenue.
- Term
- Q3 2026
“Elevance Health's third quarter results reflect stronger execution across our diversified portfolio and underscore the earnings power of the business. We are raising our 2026 earnings outlook and remain confident in delivering at least 12% growth in adjusted diluted earnings per share in 2027 from our higher earnings baseline of at least $26.75. By bringing together the capabilities of our Health Benefits business and Carelon, we are improving the healthcare experience, strengthening our competitive advantage, and creating long-term value for our shareholders.”
Gail K. Boudreaux, President and Chief Executive Officer